Method for inhibiting or reducing damage to the Thalamus in a subject comprising administering to the subject an amount of laquinimod, where the subject is a Human Patient affected by a form of Multiple Sclerosis or presents a clinically isolated Syndrome that has determined that Damage Thalamus in basal conditions,A person affected by a disease or Disorder of a different form of Multiple Sclerosis or a clinically isolated Syndrome, or a subject who is not affected by a form of Multiple Sclerosis and presents a clinically isolated Syndrome, and laquinimod and Pharmaceutical compositions Of laquinimod for use.Methods to inhibit or reduce the TREMORS and Spasticity in a subject affected by tremor or spasticity, which comprises administering to the subject an amount of laquinimod, and laquinimod and laquinimod Pharmaceutical compositions for use in the same.Laquinimod claim 51: wherein is for use in inhibition or reduction of damage to the Thalamus in a Human patient was determined to have damage Thalamus in basal conditions.Claim 52: a Pharmaceutical composition which comprises a number of laquinimod for use in inhibition or reduction of damage to the Thalamus in a Human patient was determined to have damage Thalamus in basal conditions.Método para inhibir o reducir el daño talámico en un sujeto que comprende administrarle al sujeto una cantidad de laquinimod, en donde el sujeto es un paciente humano afectado por una forma de esclerosis múltiple o que presenta un síndrome clínicamente aislado al que se le ha determinado que tiene daño talámico en condiciones basales, un sujeto afectado por una enfermedad o trastorno diferente de una forma de esclerosis múltiple o un síndrome clínicamente aislado, o un sujeto que no está afectado por una forma de esclerosis múltiple ni presenta un síndrome clínicamente aislado, y laquinimod y composiciones farmacéuticas de laquinimod para uso del mismo. Métodos para inhibir o reducir el tremor o espasticidad en un sujeto afectado por t
